LACKNER MARK (Chief Scientific Officer) sold 2.7% of their position (14.37K shares) of ZENTALIS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $24.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 2/5/2025ACC: 0001725160-25-000041
Officer· Chief Scientific Officer
Since Dec 2023
+446.25K
Net shares
Net buyer
$24.6K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
460.62K acquired · 14.37K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
+335.91K
Price / share
—
Trade value
—
% of position
175.6%
2/3/2025
191.32K→527.22K
Common Stock
Direct
Shares
−14.37K
Price / share
$1.71
Trade value
$24.59K
% of position
2.7%
2/3/2025
527.22K→512.86K
Total
Net shares
+321.54K
Net value
-$24.59K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 2/3/2025 | A · Award | +335.91K | — | — | 175.6% | 191.32K | 527.22K |
| Common Stock Direct | 2/3/2025 | S · Sale | −14.37K | $1.71 | $24.59K | 2.7% | 527.22K | 512.86K |
| Total | +321.54K | -$24.59K | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Stock
124.71K shares
Shares
+124.71K
Strike price
1.68
Held after
124.71K
Exercisable
—
2/3/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Stock124.71K shares | 2/3/2025 | A · Award | +124.71K | 1.68 | — | 124.71K |